Skip to main content

Joan Morote Robles

Soc Coordinador de la Unitat Docent en Urologia de l'Hospital Universitari Vall d'Hebron i Cap del Grup de recerca en Urologia del Vall d'Hebron Institut de Recerca. 

Institutions of which they are part

Head of group
Biomedical Research in Urology
Vall Hebron Institut de Recerca
General Hospital
Em vaig formar com a uròleg entre el 1979 i 1981 a l'Hospital Vall d'Hebron, on he desenvolupat tota la meva carrera professional com Adjunt, Cap de Secció, Cap de Servei i ara, com a Consultor Docent Sènior i Catedràtic d'Urologia. La meva àrea d'especial dedicació ha estat el càncer de pròstata, havent-hi ates a més de 6.000 pacients. 
Actualment, soc Coordinador de la Unitat Docent Vall d'Hebron i cap del grup de recerca en urologia del VHIR on estic desenvolupant un projecte de recerca sobre radiogènica e intel·ligència artificial per a la detecció precoç del càncer de pròstata.

Research lines

Development of non-invasive methods for the early detection of prostate cancer (Translational research in prostate cancer)

One main focus of our research is the discovery of new biomarkers for the early detection of prostate cancer (PC). The detection of proteins, RNA or miRNAs from easily accessible body fluids, such as blood or urine, will make possible to diagnose the disease at an early/pre-symptomatic stage, or monitoring responses to therapy in a simple and non-invasive way. This will improve the specificity of the currently used PSA serum measurements. We have identified a three-gene panel in urine able to increase the PSA specificity for the detection of PC, and using liquid chromatography, mass spectrometry and triple quadruple mass spectrometry (LC/MSMS, SRM), we have discovered the presence of specific, differential proteomic profiles in the urine of PC patients. Furthermore, we have identified a genomic profile able to detect PC in patients previously diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN). Such profile should have an application in the clinics and improve decision making in the diagnosis and treatment of PC (Figure). 1) Sequeiros T, et al. Prostate 2015; Accepted; 2) Rigau M*, Olivan M*, et al. Int. J. Mol. Sci. 2013;14: 12620-12649; 3) Rigau M, et al. Prostate 2011; 71:1736-45; 4) Rigau M et al. Prostate 2010; 70:1760-7

IP: Joan Morote Robles

miRNAs and metastasic prostate cancer (Translational research in prostate cancer)

It is still difficult by current risk stratification strategies, to distinguish patients with rapidly progressing PC, requiring aggressive treatment, from those with an indolent tumour that will not progress. One aim of our group is to identify miRNA signatures that closely correlate with clinical outcome of PC and characterize the role in cancer progression of the most relevant miRNAs associated to the metastatic profile in order to identify new potential therapeutic targets for aggressive PC. Sequeiros T*, Garcia M*, et al. BioMed Research Int?2013; doi:10.1155/2013/283635

IP: Joan Morote Robles

Bone metastases in prostate cancer (Translational research in prostate cancer)

Once the tumor metastasizes to bone, the metastatic disease become incurable and current therapies are palliative. Thus, to better understand the biology of PC bone metastasis and to investigate new therapeutic options it is crucial to develop new animal models. We have established new experimental models of PC bone metastasis by inoculation (intratibial and intracardiac) of human PC cell lines in immunodeficient mice to make a suitable model for evaluating novel compounds as future therapeutic approaches. Extensive bone metastases were monitored by in vivo bioluminescence imaging. By applying different strategies we have described new molecular targets involved in the mechanisms of PC bone metastasis. 1) Garcia M, et al. BJU Int. 2014;113:E164-77. 2) Doll A, et al. Arch Esp Urol. 2013;66:463-74.

IP: Joan Morote Robles

Early diagnosis and staging of prostate cancer (Clinical research)

This research line evaluates better strategies able to improve the process of Early Diagnosis of Prostate Cancer, detecting significant tumors and avoiding unnecessary biopsies. In addition, this line also studies the outcomes of the Active Surveillance Program and the Robotic Program.

IP: Joan Morote Robles, Ana Celma Domènech


Radiogenomics for the prediction of prostate cancer aggressiveness through artificial intelligence.

IP: Joan Morote Robles
Collaborators: Leticia Suarez Cabrera, Inés de Torres Ramirez, Marta Barber Servera, Ana Celma Domènech, Adrian Garcia Rodriguez, Jacques Planas Morin, Richard Mast
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI20/01666
Duration: 01/01/2021 - 31/12/2023


IP: Joan Morote Robles
Collaborators: -
Funding agency:
Reference: PR(AG)190/2019
Duration: -

Noves estratègies terapèutiques pel tractament del càncer de pròstata hormonorefrectari

IP: Joan Morote Robles
Collaborators: Marta Barber Servera, Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 52963.21
Reference: 2020FI_B 00058
Duration: 01/09/2020 - 31/08/2023

FPII per Grup d'Investigació en Urología

IP: Joan Morote Robles
Collaborators: Adrian Garcia Rodriguez, Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 35800
Reference: PEJ2018-002742-A
Duration: 01/09/2019 - 31/08/2021

Related news

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

The drug EB1 is able to block resistance pathways to standard cancer treatments and could increase the efficacy of chemotherapy or immunotherapy.

Durant el mes de juny, organitzem tres activitats sobre assaigs clínics, genètica i imatges científiques.

Related professionals

Olga Mendez Fernández

Olga Mendez Fernández

Postdoctoral researcher
Biomedical Research in Urology
Read more
Jacques Planas Morin

Jacques Planas Morin

Biomedical Research in Urology
Read more
Richard Mast

Richard Mast

Read more
David Ruiz Casajuana

David Ruiz Casajuana

Research technician
Biomedical Research in Urology
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.